Stay updated on Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    7 days ago
    Change Detected
    Summary
    No significant changes detected in core content; only cosmetic formatting changes were observed on the Study Details page, and there are no updates to inclusion criteria, primary outcomes, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T01:27:12.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    36 days ago
    Change Detected
    Summary
    The page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.
    Difference
    2%
    Check dated 2025-10-05T10:31:00.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    Terminology updated from 'Plasma cell myeloma' to 'Multiple myeloma' and page version bumped from v3.0.2 to v3.1.0.
    Difference
    0.1%
    Check dated 2025-09-28T03:20:24.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    The page revision was updated from v3.0.1 to v3.0.2, and the 'Back to Top' link was removed.
    Difference
    0.1%
    Check dated 2025-09-13T17:45:41.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.1%
    Check dated 2025-09-06T15:28:45.000Z thumbnail image
  8. Check
    72 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name and location, as well as new medical terms related to plasma cell myeloma and various compounds. Notably, several previous terms related to multiple myeloma treatments have been removed.
    Difference
    2%
    Check dated 2025-08-30T12:18:20.000Z thumbnail image

Stay in the know with updates to Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.